Broker Regulation

The lawsuit alleges that Cigna worked with a drug-benefit middleman to drain J&J financial-assistance funds.

Immediately, Trump's new Health appointees were met with a rash of strong reactions from assorted media outlets.

Complex formulary structures, high initial pricing, entrenched market advantages favoring established brands, and hesitancy among prescribers and patients have slowed adoption, leaving billions in savings untapped.

For benefits professionals, compliance is more than an obligation—it's an opportunity to streamline care access, reduce frustrations, and enhance the overall employee benefits experience.

It is hard to predict what the incoming federal administration will do with respect to PBM laws, but it seems that the states will continue to make this a focus.

Many HR and technology leaders want to grow in their understanding of the potential for bias in employee benefits technology.